Fidelity Investments
FTH

Fidelity Investments’s Faeth Therapeutics FTH Stock Holding History

Fidelity Investments’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Hold
0
– -$9 – 5496
2023
Q2 		– Hold
0
– – – 5281
2022
Q3 		– Sell
-10
Closed – – 5352
2022
Q2 		$0 Buy
10
+1
+11% +$37 ﹤0.01% 5436
2022
Q1 		$0 Buy
+9
New +$716 ﹤0.01% 5433

Other funds holding FTH

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments's FTH Position: Q3 2023 in Review

Fidelity Investments held its Faeth Therapeutics (FTH) position steady in Q3 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5496.

Fidelity Investments first reported a position in FTH in Q1 2022 and has held it in 2 quarters since. The position peaked at $0 in Q2 2022. 21 funds tracked by Wall St. Rank hold FTH as of Q3 2023.

  • Fidelity Investments held 0 shares of Faeth Therapeutics worth $0 as of Q3 2023.
  • Fidelity Investments left its Faeth Therapeutics share count unchanged in Q3 2023.
  • Faeth Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2023, its #5496 holding.
  • Fidelity Investments first reported a position in Faeth Therapeutics in Q1 2022 and has held it in 2 quarters since.
  • Fidelity Investments's Faeth Therapeutics position peaked at $0 in Q2 2022.
  • 21 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2023.

Based on Fidelity Investments's 13F filing for Q3 2023, filed 13 Nov 2023.